← Leaderboards
Jung-Im Shin
Johns Hopkins University
$1,346,437
Attributed
$1,346,437
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $731.1K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,346,437 · 2
By mechanism
R01$731,071 · 1
K01$615,366 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Josephine M Egan$65,169
- Ayobami T Akenroye$1,708,103
- Brendan K Saloner$4,311,375
- Ann L Hubbard$8,391,068
- Jeremy Sugarman$6,281,225
Others in their field
Other Emerging Leaders on “Race”
- Chanza Baytop · Westat, Inc.$271,217,917
- Abraham Aizer Brody · New York University School Of Medicine$16,749,445
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$14,031,836
- Michael P Harms · Washington University$13,645,932
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$12,505,706
- Bjorn E Oskarsson · Mayo Clinic Jacksonville$11,846,278
Research focus
RaceCharacteristicsGuidelinesPharmaceutical PreparationsSodiumIndividual PatientEndocrinologistGlucoseHyperglycemiaMediatingRecommendationSocioeconomic StatusCostCohortCaringDiabetes MellitusEnd Stage Renal FailureGlp-I ReceptorCardiovascular DiseasesAgonistConsensusCreatinineAgreementAntidiabetic Drugs
Grant awards (5)
Challenges to Guideline-Recommended Diabetes Care in the United States$731,071
R01 · FY2025 · DK · contact PI
The Comparative Effectiveness and Safety of Second-line Therapy in Patients with Type 2 Diabetes$150,982
K01 · FY2022 · DK · contact PI
The Comparative Effectiveness and Safety of Second-line Therapy in Patients with Type 2 Diabetes$150,982
K01 · FY2021 · DK · contact PI
The Comparative Effectiveness and Safety of Second-line Therapy in Patients with Type 2 Diabetes$154,894
K01 · FY2020 · DK · contact PI
The Comparative Effectiveness and Safety of Second-line Therapy in Patients with Type 2 Diabetes$158,508
K01 · FY2019 · DK · contact PI